- Home
- DECK vs BNTX Comparison
DECK vs BNTX Comparison
Compare DECK & BNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DECK | BNTX |
|---|---|---|
| Founded | 1973 | 2008 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9B | 24.8B |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DECK | BNTX |
|---|---|---|
| Price | $109.09 | $103.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 11 |
| Target Price | $122.20 | ★ $140.31 |
| AVG Volume (30 Days) | ★ 2.0M | 575.0K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.04 | N/A |
| Revenue | ★ $4,985,612,000.00 | N/A |
| Revenue This Year | $11.16 | $2.58 |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | $18.19 | ★ N/A |
| Revenue Growth | ★ 16.28 | N/A |
| 52 Week Low | $78.91 | $90.12 |
| 52 Week High | $137.23 | $124.00 |
Technical Indicators
Market Signals| Indicator | DECK | BNTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 43.14 |
| Support Level | $96.70 | $99.63 |
| Resistance Level | $110.26 | $104.05 |
| Average True Range (ATR) | 3.56 | 3.05 |
| MACD | -1.47 | -0.88 |
| Stochastic Oscillator | 14.21 | 44.06 |
Price Performance
Historical ComparisonAbout DECK Deckers Outdoor Corporation
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2025, Ugg and Hoka accounted for 51% and 45% of total sales, respectively. The firm also markets a niche sandal brand called Teva. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and has more than 200 company-operated stores. It generated 64% of its fiscal 2025 sales in the United States.
About BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.